These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 26198921)

  • 1. A phase IIa randomized clinical study testing GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis associated endogenous retrovirus in multiple sclerosis patients - a twelve month follow-up.
    Derfuss T; Curtin F; Guebelin C; Bridel C; Rasenack M; Matthey A; Du Pasquier R; Schluep M; Desmeules J; Lang AB; Perron H; Faucard R; Porchet H; Hartung HP; Kappos L; Lalive PH
    J Neuroimmunol; 2015 Aug; 285():68-70. PubMed ID: 26198921
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A phase IIa randomised clinical study of GNbAC1, a humanised monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus in multiple sclerosis patients.
    Derfuss T; Curtin F; Guebelin C; Bridel C; Rasenack M; Matthey A; Du Pasquier R; Schluep M; Desmeules J; Lang AB; Perron H; Faucard R; Porchet H; Hartung HP; Kappos L; Lalive PH
    Mult Scler; 2015 Jun; 21(7):885-93. PubMed ID: 25392325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GNbAC1, a humanized monoclonal antibody against the envelope protein of multiple sclerosis-associated endogenous retrovirus: a first-in-humans randomized clinical study.
    Curtin F; Lang AB; Perron H; Laumonier M; Vidal V; Porchet HC; Hartung HP
    Clin Ther; 2012 Dec; 34(12):2268-78. PubMed ID: 23200102
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical and early clinical development of GNbAC1, a humanized IgG4 monoclonal antibody targeting endogenous retroviral MSRV-Env protein.
    Curtin F; Perron H; Kromminga A; Porchet H; Lang AB
    MAbs; 2015; 7(1):265-75. PubMed ID: 25427053
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment against human endogenous retrovirus: a possible personalized medicine approach for multiple sclerosis.
    Curtin F; Perron H; Faucard R; Porchet H; Lang AB
    Mol Diagn Ther; 2015 Oct; 19(5):255-65. PubMed ID: 26376649
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A new therapeutic approach for type 1 diabetes: Rationale for GNbAC1, an anti-HERV-W-Env monoclonal antibody.
    Curtin F; Bernard C; Levet S; Perron H; Porchet H; Médina J; Malpass S; Lloyd D; Simpson R;
    Diabetes Obes Metab; 2018 Sep; 20(9):2075-2084. PubMed ID: 29749030
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MSRV envelope protein is a potent, endogenous and pathogenic agonist of human toll-like receptor 4: Relevance of GNbAC1 in multiple sclerosis treatment.
    Madeira A; Burgelin I; Perron H; Curtin F; Lang AB; Faucard R
    J Neuroimmunol; 2016 Feb; 291():29-38. PubMed ID: 26857492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The neutralizing antibody GNbAC1 abrogates HERV-W envelope protein-mediated oligodendroglial maturation blockade.
    Kremer D; Förster M; Schichel T; Göttle P; Hartung HP; Perron H; Küry P
    Mult Scler; 2015 Aug; 21(9):1200-3. PubMed ID: 25480862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum pharmacokinetics and cerebrospinal fluid concentration analysis of the new IgG4 monoclonal antibody GNbAC1 to treat multiple sclerosis: A Phase 1 study.
    Curtin F; Vidal V; Bernard C; Kromminga A; Lang AB; Porchet H
    MAbs; 2016 Jul; 8(5):854-60. PubMed ID: 27030142
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A placebo randomized controlled study to test the efficacy and safety of GNbAC1, a monoclonal antibody for the treatment of multiple sclerosis - Rationale and design.
    Curtin F; Porchet H; Glanzman R; Schneble HM; Vidal V; Audoli-Inthavong ML; Lambert E; Hartung HP
    Mult Scler Relat Disord; 2016 Sep; 9():95-100. PubMed ID: 27645352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human Endogenous Retrovirus and Neuroinflammation in Chronic Inflammatory Demyelinating Polyradiculoneuropathy.
    Faucard R; Madeira A; Gehin N; Authier FJ; Panaite PA; Lesage C; Burgelin I; Bertel M; Bernard C; Curtin F; Lang AB; Steck AJ; Perron H; Kuntzer T; Créange A
    EBioMedicine; 2016 Apr; 6():190-198. PubMed ID: 27211560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A High-dose Pharmacokinetic Study of a New IgG4 Monoclonal Antibody Temelimab/GNbAC1 Antagonist of an Endogenous Retroviral Protein pHERV-W Env.
    Porchet H; Vidal V; Kornmann G; Malpass S; Curtin F
    Clin Ther; 2019 Sep; 41(9):1737-1746. PubMed ID: 31311668
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do Antiretroviral Drugs Protect From Multiple Sclerosis by Inhibiting Expression of MS-Associated Retrovirus?
    Morandi E; Tanasescu R; Tarlinton RE; Constantin-Teodosiu D; Gran B
    Front Immunol; 2018; 9():3092. PubMed ID: 30740110
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The monoclonal antibody GNbAC1: targeting human endogenous retroviruses in multiple sclerosis.
    Diebold M; Derfuss T
    Ther Adv Neurol Disord; 2019; 12():1756286419833574. PubMed ID: 30873219
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correlation between disease severity and in vitro cytokine production mediated by MSRV (multiple sclerosis associated retroviral element) envelope protein in patients with multiple sclerosis.
    Rolland A; Jouvin-Marche E; Saresella M; Ferrante P; Cavaretta R; Créange A; Marche P; Perron H
    J Neuroimmunol; 2005 Mar; 160(1-2):195-203. PubMed ID: 15710473
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Natalizumab inhibits the expression of human endogenous retroviruses of the W family in multiple sclerosis patients: a longitudinal cohort study.
    Arru G; Leoni S; Pugliatti M; Mei A; Serra C; Delogu LG; Manetti R; Dolei A; Sotgiu S; Mameli G
    Mult Scler; 2014 Feb; 20(2):174-82. PubMed ID: 23877972
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Multiple sclerosis retrovirus particles and recombinant envelope trigger an abnormal immune response in vitro, by inducing polyclonal Vbeta16 T-lymphocyte activation.
    Perron H; Jouvin-Marche E; Michel M; Ounanian-Paraz A; Camelo S; Dumon A; Jolivet-Reynaud C; Marcel F; Souillet Y; Borel E; Gebuhrer L; Santoro L; Marcel S; Seigneurin JM; Marche PN; Lafon M
    Virology; 2001 Sep; 287(2):321-32. PubMed ID: 11531410
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endogenous retroviral genes, Herpesviruses and gender in Multiple Sclerosis.
    Perron H; Bernard C; Bertrand JB; Lang AB; Popa I; Sanhadji K; Portoukalian J
    J Neurol Sci; 2009 Nov; 286(1-2):65-72. PubMed ID: 19447411
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Temelimab, an IgG4 Anti-Human Endogenous Retrovirus Monoclonal Antibody: An Early Development Safety Review.
    Kornmann G; Curtin F
    Drug Saf; 2020 Dec; 43(12):1287-1296. PubMed ID: 32794123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel reliable real-time PCR for differential detection of MSRVenv and syncytin-1 in RNA and DNA from patients with multiple sclerosis.
    Mameli G; Poddighe L; Astone V; Delogu G; Arru G; Sotgiu S; Serra C; Dolei A
    J Virol Methods; 2009 Oct; 161(1):98-106. PubMed ID: 19505508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.